Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Key Inclusion Criteria: * Male and female adult patients at least 18 years of age on day of signing informed consent * Histologically confirmed non-small cell lung cancer (NSCLC) adenocarcinoma * Advanced (stage IIIb) disease that is not amenable to curative intent treatment with concurrent chemoradiation and metastatic (stage IV) patients * Progressed clinically and/or radiographically per RECIST v1.1 after receiving a PD-1 or PD-L1 antagonist for a minimum of 12 weeks * Measurable disease per RECIST v1.1 * Disease that can be safely accessed via bronchoscopic, thoracoscopic or percutaneous biopsy for multiple core biopsies and participant is willing to provide tissue from newly obtain biopsies on study in a subgroup of patients * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Adequate organ function * Highly effective birth control * Able to swallow and absorb oral tablets Key Exclusion Criteria: * Current use of NSAIDs, COX-2 inhibitors * Known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS gene alteration * No history of smoking (≤100 cigarettes lifetime) * History of severe hypersensitivity reactions to a PD-1/L1 antibody * Received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment or 5 half-lives, whichever is shorter * Received prior radiotherapy within 2 weeks of start of study treatment * Has received a live vaccine within 30 days prior to the first dose of study treatment * Taking strong CYP3A4 or P-glycoprotein inhibitors or inducers * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment * Known additional malignancy that is progressing or has required active treatment within the past 3 years (with some permitted exceptions) * Known active CNS metastases and/or carcinomatous meningitis * Active autoimmune disease that has required systemic treatment in past 2 years * History of pneumonitis that required steroids or has current pneumonitis * Has an active infection requiring systemic therapy * Recent or current GI ulcer, colitis or non-immune colitis * Known history of human immunodeficiency virus (HIV) infection, or known active Hepatitis B, or Hepatitis C virus infection * Has had an allogeneic tissue/solid organ transplant * Clinically significant (i.e.active) cardiovascular disease